Skip to main content
. 2022 Feb 3;12:1839. doi: 10.1038/s41598-022-05771-1

Figure 3.

Figure 3

Myxovirus resistance protein A (MxA) levels in both treatment groups (A = IFN beta-1a group; B = placebo group) according to the presence of IFN beta-1a neutralizing antibodies (NABS) (Y = yes, elevated levels; N = elevated levels not detected).